Atara Q2 net loss $71.1M; IND cleared for ATA3219; tab-cel BLA meeting scheduled

Atara Biotherapeutics, Inc.

2023-Q2 EPS reported -$1.40 revenue$2,183,000

Net loss of $71.1M ($0.68 per share) vs net income of $18.5M ($0.18) in Q2 2022, which included one-time gains.
Cash, equivalents and investments $153.6M as of June 30, 2023; expected runway into Q2 2024 (net cash used in ops $52.8M in Q2).
IND cleared for allogeneic CAR T ATA3219 in relapsed/refractory B-cell NHL; Phase 1 to start in coming months.
FDA meeting scheduled to resolve comparability for tab-cel (EBVALLO) BLA submission; commercial discussions advancing.
Primary analysis of ATA188 Phase 2 EMBOLD study in progressive MS to be communicated in early November with data from >90 patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Atara Biotherapeutics, Inc. reported second quarter ended June 30, 2023 results: net income net loss of $71.1 million, or $0.68 per share for the second quarter 2023.

Period: second quarter ended June 30, 2023
Net income: net loss of $71.1 million, or $0.68 per share for the second quarter 2023
Result: reported results

Exact text from the filing

Atara reported a net loss of $71.1 million, or $0.68 per share for the second quarter 2023, as compared to net income of $18.5 million, or $0.18 per share for the same period in 2022.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039797

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.